The Toxicology Investigators Consortium Case Registry—the 2017 Annual Report
The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. The objective of this eighth annual report is to summarize the Registry’s 2017 data and activity with its additional 7577 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2017. Detailed data was collected from these cases and aggregated to provide information which includes demographics (e.g., age, gender, race, ethnicity), reason for medical toxicology evaluation (e.g., intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (e.g., vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality, and life support withdrawal data. Females were involved in 50.4% of cases. Transgender demographic information collection was initiated in 2017 to better represent the population and there were 36 cases involving transgender patients. Adults aged 19–65 were the most commonly reported age group. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen again the most common agent reported. There were 93 fatalities reported in 2017. Treatment interventions were frequently reported with 30.6% receiving specific antidotal therapy. Major trends in demographics and exposure characteristics remained similar to past years’ reports. While treatment interventions were commonly required, fatalities were rare.
KeywordsPoisonings Overdose Surveillance Epidemiology Medical toxicology
Toxicology Investigators Consortium (ToxIC) Study Group Collaborators:
Algren DA, Alwasiyah D, Beauchamp GA, Bentur Y, Berman AJ, Beuhler MC, Biary R, Bonney C, Boyle KL, Bruccoleri RC, Burns MM, Cahana A, Cannon RD, Caravati EM, Carey J, Chiba T, Christian M, Cook MD, Cumpston K, Davis A, Dribben W, Eisenga BH, Eldos Y, Falkowitz DM, Farkas A, Finkelstein Y, Fisher E, Froberg BA, Ganetsky M, Garlich F, Geib AJ, Gittinger M, Gorodetsky R, Greene SC, Hart K, Hendrickson RG, Hernandez S, Hodgman M, Hoyte C, Judge BS, Kao L, Katz KD, Kessler BD, King JD, Kirschner RI, Kostic M, Leikin JB, Levine M, Lowry JA, Lurie Y, Majlesi N, Malashock H, Manini AF, Marino R, McKay CA Jr., McKeever R, McKeown N, Meadors K, Moore E, Morgan B, Mullins ME, Nacca NE, Niruntarai S, Nogar JN, Olmedo R, Othong R, Riley BD, Rusyniak DE, Schimmel J, Schult R, Schwarz ES, Scoccimarro A, Seifert SA, Shafer S, Smith S, Smolinske SC, Spyres M, Steck A, Stripp M, Sullivan R, Theobald J, Troendle M, Vearrier, Warrick BJ, Watts D, Wills B, Zosel AE.
We also wish to thank study coordinators AB Adefeso, D Hopkins, Julie Licata, Tammy Phan, Andrea Ramirez, Mellissa VandenBerg, and Love Wilson.
This study received funding from the NIH National Institute on Drug Abuse, 1R56DA38366 and 1R01DA037317-01, a data sharing contract with the US Food and Drug Administration and BTG International Inc. (North America).
Compliance with Ethical Standards
Conflicts of Interest
Previous Presentation of Data
- 12.Center for Behavioral Health Statistics and Quality. 2016 national survey on drug use and health: detailed tables. Substance Abuse and Mental Health Services Administration, Rockville, MD 2017.Google Scholar
- 13.Ouellette L, Cearley M, Judge B, Riley B, Jones J. Cooking with cannabis: the rapid spread of (mis)information on YouTube. Am J Emerg Med 2017.Google Scholar
- 16.Sierzant C, Judge B. Cooking with cannabis: severe toxicity following the use of cannabutter. Clin Toxicol. 2016;54:708.Google Scholar
- 17.FDA (U.S. Food and Drug Administration). 2011. Neurontin® (gabapentin) capsules, Neurontin® (gabapentin) tablets, Neurontin® (gabapentin) oral solution. NDA 020235/S-036; NDA 020882/S-022; NDA 021129/S-022 FDA Approved Labeling Text dated 03/01/2011. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s036,020882s022,021129s022lbl.pdf; accessed 12 Feb 2018.
- 18.FDA. 2012. Highlights of prescribing information: Lyrica (pregabalin) capsules, CV Lyrica (pregabalin) oral solution, CV. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021446s028lbl.pdf; accessed 12 Feb 2018.
- 20.Office for National Statistics [United Kingdom]. 2017. Death related to drug poisoning in England and Wales from 1993 onwards, by cause of death, sex, age and substances involved in the death. Latest release: Deaths related to drug poisoning in England and Wales: 2016 registrations, Released: 2 Aug 2017. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2016registrations; accessed 12 Feb 2018.